A 21-week open-label clinical trial of pregabalin as adjunctive therapy in partial seizures at multiple centers in Mexico (PREPS Mexico)

Epilepsy Research

Volumn 100, Issue 1-2, 2012, Pages 74-79

  Rivera Castaño, Leopoldo ^a   Leal Cantu, Raul ^b   Abreu, Paula ^c   Guerrero, Marita ^c   Davila, Gabriela ^c  

^a CIMA Centro Internacional de Medicina Consultorio 16   (Mexico)

^b HOSPITAL GENERAL DR MIGUEL SILVA   (Mexico)

^c PFIZER INC   (United States)

Author keywords

Adjunctive; Efficacy; Open label; Partial seizures; Pregabalin; Tolerability

Indexed keywords

CARBAMAZEPINE; PREGABALIN; TOPIRAMATE; VALPROIC ACID;

ADULT; AGED; ANXIETY; ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE DURATION; DISEASE SEVERITY; DIZZINESS; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FOCAL EPILEPSY; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEXICO; MULTICENTER STUDY; NAUSEA; OBSERVATIONAL STUDY; OPEN STUDY; OPTIMAL DRUG DOSE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; SIDE EFFECT; SLEEP DISORDER; SLEEP QUALITY; SOMNOLENCE; TREATMENT DURATION; VERTIGO; WEIGHT GAIN;

ADOLESCENT; ADULT; AGED; ANTICONVULSANTS; DRUG THERAPY, COMBINATION; EPILEPSIES, PARTIAL; FEMALE; GAMMA-AMINOBUTYRIC ACID; HUMANS; MALE; MEXICO; MIDDLE AGED; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84861532106     PISSN: 09201211     EISSN: 18726844     Source Type: Journal    
DOI: 10.1016/j.eplepsyres.2012.01.009     Document Type: Article

References (21)

1. Arikkath J., Campbell K.P. Auxiliary subunits: essential components of the voltage-gated calcium channel complex. Curr. Opin. Neurobiol. 2003, 13:298-307.
2. Arroyo S., Anhut H., Kugler A.R., Lee C.M., Knapp L.E., Garofalo E.A., Messmer S. Pregabalin add-on treatment: a randomized, double-blind, placebo-controlled, dose-response study in adults with partial seizures. Epilepsia 2004, 45:20-27. Pregabalin 1008-011 International Study Group.
3. Ben-Menachem E. Pregabalin pharmacology and its relevance to clinical practice. Epilepsia 2004, 45(Suppl. 6):13-18.
4. Beydoun A., Uthman B.M., Kugler A.R., Greiner M.J., Knapp L.E., Garofalo E.A. Safety and efficacy of two pregabalin regimens for add-on treatment of partial epilepsy. Neurology 2005, 64:475-480. Pregabalin 1008-009 Study Group.
5. Brodie M.J., Wilson E.A., Wesche D.L., Alvey C.W., Randinitis E.J., Posvar E.L., Hounslow N.J., Bron N.J., Gibson G.L., Bockbrader H.N. Pregabalin drug interaction studies: lack of effect on the pharmacokinetics of carbamazepine, phenytoin, lamotrigine, and valproate in patients with partial epilepsy. Epilepsia 2005, 46:1407-1413.
6. de Haas S., Otte A., de Weerd A., van Erp G., Cohen A., van Gerven J. Exploratory polysomnographic evaluation of pregabalin on sleep disturbance in patients with epilepsy. J. Clin. Sleep Med. 2007, 3:473-478.
7. de Weerd A., de Haas S., Otte A., Trenité D.K., van Erp G., Cohen A., de Kam M., van Gerven J. Subjective sleep disturbance in patients with partial epilepsy: a questionnaire-based study on prevalence and impact on quality of life. Epilepsia 2004, 45:1397-1404.
8. 2δ ligands: novel modulators of neurotransmission. Trends Pharmacol. Sci. 2007, 28:75-82.
9. Elger C.E., Brodie M.J., Anhut H., Lee C.M., Barrett J.A. Pregabalin add-on treatment in patients with partial seizures: a novel evaluation of flexible-dose and fixed-dose treatment in a double-blind, placebo-controlled study. Epilepsia 2005, 46:1926-1936.
10. French J.A. Proof of efficacy trials: endpoints. Epilepsy Res. 2001, 45:53-56.
11. French J.A., Kugler A.R., Robbins J.L., Knapp L.E., Garofalo E.A. Dose-response trial of pregabalin adjunctive therapy in patients with partial seizures. Neurology 2003, 60:1631-1637.
12. Guy, W., 1976. Clinical global impressions. ECDEU Assessment Manual for Psychopharmacology - Revised (DHEW Pub no. ADM 76-338). U.S. Department of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, NIMH Psychopharmacology Research Branch, Division of Extramural Research Programs, Rockville, MD.
13. Hays R.D., Stewart A.L. Sleep measures. Measuring Functioning and Well Being 1992, 235-259. Duke University Press, Durham, NC. A.L. Stewart, J.E. Ware (Eds.).
14. International League Against Epilepsy Proposal for revised clinical and electroencephalographic classification of epileptic seizures. From the commission on classification and terminology of the International League Against Epilepsy. Epilepsia 1981, 22:489-501.
15. Kwan P., Brodie M.J. Combination therapy in epilepsy: when and what to use. Drugs 2006, 66:1817-1829.
16. Lozsadi D., Hemming K., Marson A.G. Pregabalin add-on for drug-resistant partial epilepsy. Cochrane Database Syst. Rev. 2008, CD005612.
17. Ryvlin P., Kälviäinen R., Von Raison F., Giordano S., Emir B., Chatamra K. Pregabalin in partial seizures: a pragmatic 21-week, open-label study (PREPS). Eur. J. Neurol. 2010, 17:726-732.
18. Ryvlin P., Perucca E., Rheims S. Pregabalin for the management of partial epilepsy. Neuropsychiatr. Dis. Treat. 2008, 4:1211-1224.
19. 2-δ (alpha2-delta) subunit as a target for antiepileptic drug discovery. Epilepsy Res. 2007, 73:137-150.
20. World Health Organization, 2009. Fact Sheet No 999: Epilepsy. (accessed 01.07.11). http://www.who.int/mediacentre/factsheets/fs999/en/index.html.
21. Zigmond A.S., Snaith R.P. The hospital anxiety and depression scale. Acta Psychiatr. Scand. 1983, 67:361-370.